Deciphera - One Mission, Inspired by Patients: Defeat Cancer.
At Deciphera, we remain steadfast in our mission to improve the lives of people living with cancer - and that passion for making a difference extends to the patient groups and communities in …
Join Us - Deciphera
At Deciphera, we are committed to building a culture that embraces the uniqueness of our people and finds strength in our differences. We understand that by creating a workplace where every …
Our Pipeline - Deciphera
Updated as of February 2024; (1) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (2) The patient population for the INSIGHT study consists …
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ …
2025年2月17日 · Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We …
Deciphera AccessPoint™ Patient Access and Support
Deciphera AccessPoint™ understands that each patient faces unique circumstances. Our dedicated Case Managers are here to help you work through challenges, from understanding …
ONO Enters into a Definitive Agreement to Acquire Deciphera ...
2024年4月30日 · Under the terms of the merger agreement, ONO will acquire all outstanding shares of Deciphera at a price of US $25.60 per share in cash, which represents a premium of …
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
2024年5月23日 · Deciphera Pharmaceuticals’ DCPH shares surged 74.3% in the past month after the cancer-focused, commercial-stage biopharmaceutical company announced entering into a …
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
2025年2月14日 · Japan's Ono pays $2.4B for Qinlock maker Deciphera as biotech readies another approval run
Deciphera Pharmaceuticals to be Acquired by ONO …
2024年4月29日 · Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO Pharmaceutical’s Pipeline and Accelerate Global …
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ …
2025年2月14日 · The FDA previously granted Fast Track designation and Priority Review for ROMVIMZA, which was developed by Deciphera Pharmaceuticals, Inc. ("Deciphera"), a wholly …